secwatch.observer — SEC 8-K summary
======================================

Issuer:     PAVmed Inc. (PAVM)
CIK:        0001624326
Form:       8-K
Filed at:   2025-03-25T23:59:59+00:00
Accession:  0001641172-25-000517
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PAVmed reports Q4 net income $1.3M; Lucid record tests, Veris financing, debt restructured
--------------------------------------------------------------------------------

- GAAP net income $1.3M ($0.12 diluted EPS); non-GAAP adjusted loss $0.7M ($0.06) per share.
- Lucid processed 4,042 EsoGuard tests in Q4 (+84% YoY); secured first insurance coverage from Highmark Blue Cross Blue Shield.
- Veris closed ~$2.4M private placement at $35M pre-money valuation to advance implantable monitor toward FDA clearance.
- PAVmed cash $1.2M at Dec 31; pro forma $3.6M including Q1 2025 private placement.
- Deconsolidation of Lucid and convertible debt restructuring added ~$25M to equity, regaining Nasdaq minimum equity compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1624326/000164117225000517/0001641172-25-000517-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1624326/000164117225000517/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-000517

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer